bluuebunny/crossref_metadata_2025_split huggingface dataset:
Draft Genome Sequence of Ureolytic Environmental Isolate
Staphylococcus
sp. NA309
Authors: Gaiero Jonathan R. , Hsiang Tom , Nicol Rob W. , Habash Marc 
Published: October 2016

ABSTRACT

We report the 2.7 Mb draft genome sequence of
Staphylococcus
sp. NA309 isolated from poultry litter. The isolate was a dominant member of the cultivable aerobic bacteria identified to have ureolytic activity, responsible for ammonia generation in poultry litter residue.
Whole-Genome Sequence of Bradyrhizobium elkanii Strain UASWS1016, a Potential Symbiotic Biofertilizer for Agriculture
Authors: Crovadore Julien , Calmin Gautier , Chablais Romain , Cochard Bastien , Schulz Torsten , Lefort François 
Published: October 2016

ABSTRACT

Bradyrhizobium elkanii
UASWS1016 has been isolated from a wet oxidation sewage plant in Italy. Fully equipped for ammonia assimilation, heavy metal resistances, and aromatic compounds degradation, it carries a large type IV secretion system, specific of plant-associated microbes. Deprived of toxins, it could be considered for agricultural and environmental uses.
Whole-Genome Sequence of Pseudomonas graminis Strain UASWS1507, a Potential Biological Control Agent and Biofertilizer Isolated in Switzerland
Authors: Crovadore Julien , Calmin Gautier , Chablais Romain , Cochard Bastien , Schulz Torsten , Lefort François 
Published: October 2016

ABSTRACT

We report here the whole-genome shotgun sequence of the strain UASWS1507 of the species
Pseudomonas graminis
, isolated in Switzerland from an apple tree. This is the first genome registered for this species, which is considered as a potential and valuable resource of biological control agents and biofertilizers for agriculture.
Biopsychosocial correlates of hope in Asian patients with cancer: a systematic review
Authors: Mahendran Rathi , Chua Shi Min , Lim Haikel A , Yee Isaac J , Tan Joyce Y S , Kua Ee Heok , Griva Konstadina 
Published: October 2016

ObjectiveTo examine the factors associated with hope and hopelessness in patients with cancer in Asian countries, and the instruments used to measure hope and hopelessness.MethordsA comprehensive systematic review was conducted with search terms, including cancer, hope, hopelessness and individual Asian country names, on CINAHL, Embase, PsycINFO, PubMed and Scopus databases. Only quantitative studies on adult cancer populations in Asia examining hope or hopelessness were included.ResultsA total of 2062 unique articles were retrieved from the databases, and 32 studies were selected for inclusion in this review. Hope and hopelessness were most frequently measured with the Herth Hope Index and the Mental Adjustment to Cancer Scale, respectively. The biopsychosocial factors that were most consistently associated with hope and hopelessness included sociodemographic variables (education, employment and economic status); clinical factors (cancer stage, physical condition and symptoms); and psychosocial factors (emotional distress, social support and connections, quality of life, control or self-efficacy, as well as adjustment and resilience).DiscussionThere is a need for more studies from South and Southeast Asia as most studies hailed from East Asia. This review highlighted the possibility of cultural differences influencing factors related to hope, suggesting that cross-cultural studies specifically would facilitate understanding behind these variations, although future reviews on hope should also include studies on hopelessness for a comprehensive understanding of the concept. Finally, more longitudinal research could be conducted to assess whether the factors associated with hope and hopelessness change over time and disease progression.
Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma
Authors: Dieng M , Cust A E , Kasparian N A , Butow P , Costa D S J , Menzies S W , Mann G J , Morton R L 
Published: October 2016

IntroductionPsychological support programmes are not currently funded for people with a history of melanoma. A major barrier to the implementation of effective psychological interventions in routine clinical care is a lack of cost-effectiveness data. This paper describes the planned economic evaluation alongside a randomised controlled trial of a psychoeducational intervention for people with a history of melanoma who are at high risk of developing new primary disease.Method and analysisThe economic evaluation is a within-trial analysis to evaluate the incremental costs and health outcomes of a psychoeducational intervention compared to usual care from the perspective of the Australian healthcare system. Cost-effectiveness and cost-utility analyses will be conducted, providing estimates of the cost to reduce fear of melanoma recurrence and the cost per quality-adjusted life-year (QALY) gained. Fear of melanoma recurrence will be measured using the Fear of Cancer Recurrence Inventory and preference-based quality of life measured using the Assessment of Quality of Life—8 Dimensions (AQoL-8D) instrument. The AQoL-8D will provide utilities for estimation of QALYs in the cost-utility analysis. Unit costs of health services and medicines will be taken from the Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme national databases. Health outcomes, and health service and medication use will be collected at baseline, 6 and 12 months follow-up. The within-trial analysis will be conducted at 12 months, consistent with the end point of the trial.Ethics and disseminationApproval to conduct the study was granted by the Sydney Local Health District (RPAH zone) Ethics Review Committee (X13-0065 and HREC/13/RPAH/86), the Department of Health and Ageing Human Research Ethics Committee (21/2013), the University of Sydney Human Research Ethics Committee (2013/595), and the Australian Institute of Health and Welfare Ethics Committee (EO 2013/4/58).Trial registration numberACTRN12613000304730; Pre-results.
Discordance between patients' stated values and treatment preferences for end-of-life care: results of a multicentre survey
Authors: Heyland Daren K , Heyland Rebecca , Dodek Peter , You John J , Sinuff Tasnim , Hiebert Tim , Jiang Xuran , Day Andrew G 
Published: October 2016

BackgroundMedical orders for the use of life-supports should be informed by patients' values and treatment preferences. The purpose of this study was to explore the internal consistency of patients' (or their family members') stated values, and the relationship between these values and expressed preferences.MethodsWe conducted a prospective study in 12 acute care hospitals in Canada. We administered a questionnaire to elderly patients and their family members about their values related to end-of-life (EOL) care, treatment preferences and decisional conflict.ResultsOf 513 patients and 366 family members approached, 278 patients (54%) and 225 family members (61%) consented to participate. Participants' most important stated values were to be comfortable and suffer as little as possible, to have more time with family, to avoid being attached to machines and tubes and that death not be prolonged. The least important stated value was that life be preserved. Based on prespecified expected associations between the various values measured, there were inconsistencies in participants' expressed value statements. With few exceptions, participants' expressed values were not associated with expected corresponding treatment preferences. Of the 109 (40%) patients and 95 (42%) family members who had made decisions about use of life-supports, 68 (56%) patients and 60 (59%) family members had decisional conflict.ConclusionsDecision-making regarding medical treatments at the EOL is inadequate. To reduce decisional conflict, patients and their families need more support to clarify their values and ensure that their preferences are grounded in adequate understanding of their illness and treatment options.Trial registration numberNCT01362855.
ASEAN’s TRADE AND FOREIGN DIRECT INVESTMENT: LONG-TERM CHALLENGES FOR ECONOMIC INTEGRATION
Authors: KAWAI MASAHIRO , NAKNOI KANDA 
Published: October 2016

This paper explores the long-term challenges for economic integration of the Association of Southeast Asian Nations (ASEAN) through trade and foreign direct investment (FDI). The region has emerged as an important production base for global multinational corporations by joining East Asia’s supply chains. While proceeding to establish the ASEAN Economic Community (AEC) by the end of 2015, ASEAN has also forged five major free trade agreements (FTAs) with its dialogue partners (China, India, Japan, Republic of Korea, and Australia–New Zealand) and is currently negotiating the Regional Comprehensive Economic Partnership. In addition, four ASEAN member states have completed Trans-Pacific Partnership negotiations. Econometric evidence suggests that (i) trade flows and inward FDI mutually reinforce each other, i.e., an increase in trade flows stimulates inward FDI and vice versa; (ii) a larger market tends to attract more inward FDI; (iii) FTAs tend to help stimulate inward FDI; and (iv) strong institutions, good physical infrastructure, and low costs of doing business are critical in boosting inward FDI. The paper suggests that in the long run it is ASEAN’s interest to further integrate itself with the rest of Asia and the world (through a Free Trade Area of the Asia-Pacific and an Asia–Europe FTA), while substantially deepening its internal integration (by moving from the AEC to a customs and economic union) and thereby maintaining ASEAN centrality.
SUPPRESSION OF ACTION TREMOR BY SENSORY ELECTRICAL STIMULATION IN PATIENTS WITH ESSENTIAL TREMOR
Authors: HEO JAE-HOON , KWON YURI , JEON HYEONG-MIN , KWON DO-YOUNG , LEE CHAN-NYEONG , PARK KEON-WOO , MANTO MARIO , KIM JI-WON , EOM GWANG-MOON 
Published: October 2016

Essential tremor (ET) is the most common movement disorder that includes postural tremor and action tremor. This study investigates whether sensory electrical stimulation (SES) is effective on the action tremor in patients with ET. One task in the clinical testing of action tremor, “Archimedes spiral drawing”, was performed in 18 patients for three sessions, which were named as pre-stimulation (PRE), stimulation on (ON), and 5[Formula: see text]min after stimulation (POST). SES (sub-motor threshold) was applied on the muscles of the elbow and wrist only at ON session. Three-dimensional (3D) angular velocities were measured on three segments (index finger, hand, and forearm) from which movements of metacarpophalangeal (MP) and wrist joints were derived. Average tremor intensity in each session was represented by root mean square of the vector sum of 3D angular velocities. Tremor intensities in ON session were smaller than in PRE session in one segment (finger) and two joints (MP and wrist) ([Formula: see text]). Tremor intensities in POST session were even smaller than in ON session in all segments and one joint (wrist) ([Formula: see text]). The results indicate that SES suppresses action tremor and the effect continues and even improves 5[Formula: see text]min after the termination of stimulation. The findings of this study may contribute to the improvement of the quality of life in patients with ET.
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process
Authors: Ohba Shigeo , Mukherjee Joydeep , Johannessen Tor-Christian , Mancini Andrew , Chow Tracy T. , Wood Matthew , Jones Lindsey , Mazor Tali , Marshall Roxanne E. , Viswanath Pavithra , Walsh Kyle M. , Perry Arie , Bell Robert J.A. , Phillips Joanna J. , Costello Joseph F. , Ronen Sabrina M. , Pieper Russell O. 
Published: October 2016

Abstract
Mutations in the isocitrate dehydrogenase gene IDH1 are common in low-grade glioma, where they result in the production of 2-hydroxyglutarate (2HG), disrupted patterns of histone methylation, and gliomagenesis. IDH1 mutations also cosegregate with mutations in the ATRX gene and the TERT promoter, suggesting that IDH mutation may drive the creation or selection of telomere-stabilizing events as part of immortalization/transformation process. To determine whether and how this may occur, we investigated the phenotype of pRb-/p53-deficient human astrocytes engineered with IDH1 wild-type (WT) or R132H-mutant (IDH1mut) genes as they progressed through their lifespan. IDH1mut expression promoted 2HG production and altered histone methylation within 20 population doublings (PD) but had no effect on telomerase expression or telomere length. Accordingly, cells expressing either IDH1WT or IDH1mut entered a telomere-induced crisis at PD 70. In contrast, only IDH1mut cells emerged from crisis, grew indefinitely in culture, and formed colonies in soft agar and tumors in vivo. Clonal populations of postcrisis IDH1mut cells displayed shared genetic alterations, but no mutations in ATRX or the TERT promoter were detected. Instead, these cells reactivated telomerase and stabilized their telomeres in association with increased histone lysine methylation (H3K4me3) and c-Myc/Max binding at the TERT promoter. Overall, these results show that although IDH1mut does not create or select for ATRX or TERT promoter mutations, it can indirectly reactivate TERT, and in doing so contribute to astrocytic immortalization and transformation. Cancer Res; 76(22); 6680–9. ©2016 AACR.
Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Authors: Wang Yan , Hsu Jung-Mao , Kang Ya'an , Wei Yongkun , Lee Pei-Chih , Chang Shing-Jyh , Hsu Yi-Hsin , Hsu Jennifer L. , Wang Hung-Ling , Chang Wei-Chao , Li Chia-Wei , Liao Hsin-Wei , Chang Shih-Shin , Xia Weiya , Ko How-Wen , Chou Chao-Kai , Fleming Jason B. , Wang Huamin , Hwang Rosa F. , Chen Yue , Qin Jun , Hung Mien-Chie 
Published: October 2016

Abstract
The oncogenic transcription factor Gli1 is a critical effector in the Hedgehog (Hh) pathway, which is necessary for the development and progression of pancreatic ductal adenocarcinoma (PDAC). Although TGFβ and K-Ras are known regulators of Gli1 gene transcription in this setting, it is not understood how Gli1 functional activity is regulated. Here, we report the identification of Gli1 as a substrate for the protein arginine N-methyltransferase PRMT1 in PDAC. We found that PRMT1 methylates Gli1 at R597, promoting its transcriptional activity by enhancing the binding of Gli1 to its target gene promoters. Interruption of Gli1 methylation attenuates oncogenic functions of Gli1 and sensitizes PDAC cells to gemcitabine treatment. In human PDAC specimens, the levels of both total Gli1 and methylated Gli1 were correlated positively with PRMT1 protein levels. Notably, PRMT1 regulated Gli1 independently of the canonical Hh pathway as well as the TGFβ/Kras-mediated noncanonical Hh pathway, thereby signifying a novel regulatory mechanism for Gli1 transcriptional activity. Taken together, our results identified a new posttranslational modification of Gli1 that underlies its pivotal oncogenic functions in PDAC. Cancer Res; 76(23); 7049–58. ©2016 AACR.
TRPA1 Mediates Aromatase Inhibitor–Evoked Pain by the Aromatase Substrate Androstenedione
Authors: De Logu Francesco , Tonello Raquel , Materazzi Serena , Nassini Romina , Fusi Camilla , Coppi Elisabetta , Li Puma Simone , Marone Ilaria M. , Sadofsky Laura R. , Morice Alyn H. , Susini Tommaso , Terreni Alessandro , Moneti Gloriano , Di Tommaso Mariarosaria , Geppetti Pierangelo , Benemei Silvia 
Published: October 2016

Abstract
Aromatase inhibitors (AI) induce painful musculoskeletal symptoms (AIMSS), which are dependent upon the pain transducing receptor TRPA1. However, as the AI concentrations required to engage TRPA1 in mice are higher than those found in the plasma of patients, we hypothesized that additional factors may cooperate to induce AIMSS. Here we report that the aromatase substrate androstenedione, unique among several steroid hormones, targeted TRPA1 in peptidergic primary sensory neurons in rodent and human cells expressing the native or recombinant channel. Androstenedione dramatically lowered the concentration of letrozole required to engage TRPA1. Notably, addition of a minimal dose of androstenedione to physiologically ineffective doses of letrozole and oxidative stress byproducts produces AIMSS-like behaviors and neurogenic inflammatory responses in mice. Elevated androstenedione levels cooperated with low letrozole concentrations and inflammatory mediators were sufficient to provoke AIMSS-like behaviors. The generation of such painful conditions by small quantities of simultaneously administered TRPA1 agonists justifies previous failure to identify a precise link between AIs and AIMSS, underscoring the potential of channel antagonists to treat AIMSS. Cancer Res; 76(23); 7024–35. ©2016 AACR.
First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Authors: Bonvalot Sylvie , Le Pechoux Cécile , De Baere Thierry , Kantor Guy , Buy Xavier , Stoeckle Eberhard , Terrier Philippe , Sargos Paul , Coindre Jean Michel , Lassau Nathalie , Ait Sarkouh Rafik , Dimitriu Mikaela , Borghi Elsa , Levy Laurent , Deutsch Eric , Soria Jean-Charles 
Published: October 2016

Abstract
Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS).
Experimental Design: Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 was injected percutaneously into tumors at 53.3 g/L. Dose escalation was based on four levels equivalent to 2.5%, 5%, 10%, and 20% of baseline TV. NBTXR3 was visualized in the tumor 24 hours postinjection, and EBRT was initiated (50 Gy over 5 weeks). Surgery was performed 6 to 8 weeks after EBRT completion.
Results: Twenty-two patients completed NBTXR3 injection, EBRT, and surgery and were followed for a median 22 months (range, 6–40). At NBTXR3 20% of TV, two dose-limiting toxicities occurred: injection-site pain and postoperative scar necrosis. The RD was defined as 10%. No leakage of NBTXR3 into surrounding tissues occurred; intratumor NBTXR3 levels were maintained during radiotherapy. At the RD, median tumor shrinkage was 40% (range 71% shrinkage, 22% increase); median percentage of residual viable tumor cells was 26% (range, 10%–90%). Patients receiving 20% of TV demonstrated pathologic complete responses. Seven grade 3 adverse events occurred, which were reversible.
Conclusions: A single intratumoral injection of NBTXR3 at 10% of TV with preoperative EBRT was technically feasible with manageable toxicity; clinical activity was observed. Clin Cancer Res; 23(4); 908–17. ©2016 AACR.
Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
Authors: Margolis Jay M. , Deitelzweig Steven , Kline Jeffrey , Tran Oth , Smith David M. , Bookhart Brahim , Crivera Concetta , Schein Jeff 
Published: October 2016

Background

Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (
LOS
) and hospitalization costs for patients with venous thromboembolism treated with rivaroxaban versus those treated with warfarin.

Methods and Results

Hospitalizations for adult patients with a primary diagnosis of deep vein thrombosis or pulmonary embolism who were initiated on rivaroxaban or warfarin were selected from MarketScan's Hospital Drug Database between November 1, 2012, and December 31, 2013. Patients treated with warfarin were matched 1:1 to patients treated with rivaroxaban using exact and propensity score matching. Hospital
LOS
, time from first dose to discharge, and hospitalization costs were reported descriptively and with generalized linear models (
GLM
s). The final study cohorts each included 1223 patients (751 with pulmonary embolism and 472 with deep vein thrombosis). Cohorts were well matched for demographic and clinical characteristics. Mean (±
SD
)
LOS
was 3.7±3.1 days for patients taking rivaroxaban and 5.2±3.7 days for patients taking warfarin, confirmed by
GLM
‐adjusted results (rivaroxaban 3.7 days, warfarin 5.3 days,
P
<0.001). Patients with provoked venous thromboembolism admissions showed longer
LOSs
(rivaroxaban 5.1±4.5 days, warfarin 6.5±5.6 days,
P
<0.001) than those with unprovoked venous thromboembolism (rivaroxaban 3.3±2.4 days, warfarin 4.8±2.8 days,
P
<0.001). Days from first dose to discharge were 2.4±1.7 for patients treated with rivaroxaban and 3.9±3.7 for patients treated with warfarin when initiated with parenteral anticoagulants (
P
<0.001), and 2.7±1.7 and 3.7±2.1, respectively, when initiated without parenteral anticoagulants (
P
<0.001). Patients initiated on rivaroxaban incurred significantly lower mean total hospitalization costs ($8688±$9927 versus $9823±$9319,
P
=0.004), confirmed by modeling (rivaroxaban $8387 [95% confidence interval, $8035–$8739]; warfarin $10 275 [95% confidence interval, $9842–$10 708]).

Conclusions

Rivaroxaban was associated with significantly shorter hospital
LOS
and lower hospitalization costs compared with warfarin.
Socioeconomic Status and the Quality of Acute Stroke Care
Authors: Pan Yuesong , Chen Ruoling , Li Zixiao , Li Hao , Zhao Xingquan , Liu Liping , Wang Chunxue , Wang Yilong , Wang Yongjun 
Published: October 2016

Background and Purpose—
The association of socioeconomic status (SES) with quality of stroke care is not well understood, and few studies have examined the association with different indicators of SES simultaneously. We assessed the impacts of low levels of education, occupation, and income on the quality of stroke care.

Methods—
We examined data from the China National Stroke Registry recording consecutive stroke patients between September 2007 and August 2008. Baseline low SES was measured using educational level <6 years, occupation as manual workers or no job, and average family income per capita at ≤¥1000 per month. Compliance with 11 performances was summarized in a composite score defined as the proportion of all needed care given. Poor quality of care was defined as having a composite score of 0.71 or less.

Results—
Among 12 270 patients with ischemic stroke, 38.6% had <6 educational years, 37.6% had manual workers/no job, and 34.7% had income ≤¥1000 per month. There was an increased chance of receiving poor quality of care in patients with low education (adjusted odds ratio 1.15, 95% confidence interval 1.03–1.28), low occupation (adjusted odds ratio 1.16, 95% confidence interval 1.01–1.32), and low income (adjusted odds ratio 1.18, 95% confidence interval 1.06–1.30), respectively. People with low SES had poor performances on some aspects of care quality. Combined effects existed among these SES indicators; those with low SES from all 3 indicators had the poorest quality of care.

Conclusions—
There was a social gradient in the quality of stroke care. Continuous efforts of socioeconomic improvement will increase the quality of acute stroke care.